The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
XNCR - Xencor, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$27.50
DETAILS
HIGH:
$29.00
LOW:
$26.00
MEDIAN:
$27.50
CONSENSUS:
$27.50
UPSIDE:
143.15%
Stock News
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.
Xencor Reports First Quarter 2026 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. “Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for t.
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease (IBD). The results are being presented today at Digestive Disease Week® (DDW), being held in Chicago. Tomorrow, the company will a.
Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving Average – What’s Next?
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $13.44 and traded as low as $11.17. Xencor shares last traded at $12.06, with a volume of 1,087,794 shares changing hands. Wall Street Analysts Forecast Growth Several research firms
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Alaska Airlines, ConocoPhillips, Commvault Systems, CoreWeave, Diamondback Energy, JFrog Ltd, Microsoft, and More
Pre-Market Stock Futures: After a volatile start to the week, futures are trading lower on Tuesday. Markets had plummeted early Monday before the opening bell, only to stage a massive turnaround following news of a potential diplomatic breakthrough. The rally was ignited by President Trump's announcement of significant progress in negotiations with Iran, alongside a... Here Are Tuesday's Top Wall Street Analyst Research Calls: Alaska Airlines, ConocoPhillips, Commvault Systems, CoreWeave, Diamondback Energy, JFrog Ltd, Microsoft, and More.
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Analysts
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling
Xencor, Inc. (NASDAQ: XNCR - Get Free Report)'s stock price gapped down before the market opened on Thursday after an insider sold shares in the company. The stock had previously closed at $12.74, but opened at $11.85. Xencor shares last traded at $11.53, with a volume of 514,772 shares trading hands. Specifically, CEO Bassil I. Dahiyat
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris.
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any.
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago.
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025. “Xencor's lead oncology drug candidate is XmAb819, a novel first-in-class T-cell engager that could offer a much-needed new therapeutic modality for patients with advanced clear cell renal cell carcinoma (ccRCC).
Xencor to Participate at Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT Leerink Partners 2026 Global Healthcare Conference Date: Tuesday, March 10, 2026 Presen.
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Analysts
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average
Xencor (NASDAQ:XNCR) Stock Passes Below Two Hundred Day Moving Average – What’s Next?
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $12.41 and traded as low as $11.76. Xencor shares last traded at $11.99, with a volume of 471,276 shares traded. Analyst Ratings Changes
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – What’s Next?
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $15.41 and traded as low as $12.50. Xencor shares last traded at $13.02, with a volume of 641,201 shares changing hands. Wall Street Analyst Weigh
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has earned an average rating of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the
Price Targets
Xencor price target raised to $26 from $23 at Barclays
$26.00
(was $16.55)
Barclays
Xencor initiated with a Buy at Truist
$29.00
(was $15.87)
Truist Financial
Xencor price target raised to $42 from $40 at Cantor Fitzgerald
$42.00
(was $14.75)
Cantor Fitzgerald
Xencor upgraded to Overweight from Underweight at Barclays
$23.00
(was $14.25)
Etzer Darout
·
Barclays
Xencor price target raised to $18 from $15 at RBC Capital
$18.00
(was $13.83)
Gregory Renza
·
RBC Capital
Xencor assumed with an Underweight at Barclays
$6.00
(was $8.62)
Barclays
Xencor price target lowered to $26 from $31 at Wedbush
$26.00
(was $7.32)
David Nierengarten
·
Wedbush
Xencor price target lowered to $31 from $38 at Wedbush
$31.00
(was $15.36)
Wedbush
Piper Sandler Upgrades Xencor, Inc. (XNCR) to Overweight
$30.00
(was $25.60)
Edward Tenthoff
·
Piper Sandler
Xencor, Inc. (XNCR) PT Lowered to $32 at BMO Capital
$32.00
(was $20.89)
Etzer Darout
·
BMO Capital
Xencor, Inc. (XNCR) PT Lowered to $31 at RBC Capital
$31.00
(was $20.99)
Gregory Renza
·
RBC Capital
Xencor, Inc. (XNCR) PT Lowered to $38 at BTIG
$38.00
(was $20.11)
Kaveri Pohlman
·
BTIG
Xencor, Inc. (XNCR) PT Raised to $54 at Guggenheim, Following Strategic Business Update
$54.00
(was $35.52)
Charles Zhu
·
Guggenheim
Xencor (XNCR) Received its Third Buy in a Row
$58.00
(was $40.76)
Dane Leone
·
Raymond James